Frontiers in Endocrinology,
Год журнала:
2025,
Номер
15
Опубликована: Янв. 21, 2025
Nucleotide-binding
oligomerization
domain
1
(NOD1)
is
an
intracellular
pattern
recognition
receptor
that
detects
injury
signals
and
initiates
inflammatory
responses
host
defense.
Furthermore,
NOD1
serves
as
a
metabolic
mediator
by
influencing
the
metabolism
of
various
tissues,
including
adipose
tissue,
liver,
cardiovascular
pancreatic
β
cells,
adrenal
glands,
bones
through
diverse
mechanisms.
It
has
been
discovered
activated
associated
with
pathological
mechanisms
certain
diseases.
This
review
presents
comprehensive
summary
impact
on
tissue-specific
metabolism.
International Journal of Translational Medicine,
Год журнала:
2025,
Номер
5(1), С. 7 - 7
Опубликована: Янв. 17, 2025
Metabolic
dysfunction-associated
steatohepatitis
(MASH)
is
rapidly
becoming
a
leading
cause
of
hepatocellular
carcinoma
and
end-stage
liver
transplantation.
Characterized
by
hepatic
steatosis,
lobular
inflammation,
hepatocyte
ballooning,
there
dire
need
to
develop
therapeutic
strategies
mitigate
MASH
alongside
the
subsequent
fibrosis
cirrhosis.
For
years,
development
for
treatment
had
been
considered
graveyard,
with
various
pharmacotherapies
failing
achieve
clinical
efficacy.
However,
recent
Food
Drug
Administration
(FDA)
approval
Madrigal
Pharmaceuticals’
Resmetirom
in
United
States
provides
positive
step
collective
effort
eradicate
MASH.
Granted,
much
about
Resmetirom’s
long-term
efficacy
safety
still
be
determined
multi-factorial
nature
pathogenesis,
continuing
evaluate
alternative
options
remains
best
interest
field.
Currently,
therapeutics
previously
approved
other
ailments,
novel
developed
specifically
MASH,
are
being
evaluated
late-phase
trials.
considering
complex
disease
varying
outcomes
assess
efficacy,
achieving
regulatory
as
continues
rigorous
endeavor.
In
this
review,
we
summarize
notable
mechanistic
backgrounds
having
achieved,
or
actively
undergoing,
trials
offer
our
perspectives
on
anti-MASH
development.
Frontiers in Immunology,
Год журнала:
2025,
Номер
16
Опубликована: Янв. 22, 2025
Objective
T
cell-mediated
rejection
(TCMR)
remains
a
significant
challenge
in
organ
transplantation.
This
study
aimed
to
define
TCMR-associated
cytokine
gene
set
and
identify
drugs
prevent
TCMR
through
drug
repurposing.
Methods
Gene
expression
profiles
from
kidney,
heart,
lung
transplant
biopsies
were
obtained
the
Expression
Omnibus
(GEO)
database.
Differentially
expressed
genes
(DEGs)
between
non-TCMR
groups
identified,
their
intersection
with
cytokine-related
yielded
an
11-gene
(TCMR-Cs).
To
evaluate
effectiveness
of
this
set,
diagnostic
predictive
model
was
constructed
using
Lasso
regression
multivariate
logistic
regression,
validation
independent
datasets.
Connectivity
Map
(CMap)
analysis
employed
screen
targeting
TCMR-Cs.
Experimental
identified
performed
vitro
cell
activation
Th1
differentiation
assays,
vivo
mouse
skin
survival
analysis.
Results
The
TCMR-Cs
exhibited
outstanding
performance
for
TCMR,
achieving
AUC
0.99
training
cohorts
maintaining
strong
test
cohorts.
CMap
peroxisome
proliferator-activated
receptor
gamma
(PPARγ)
agonists
as
potential
therapeutic
candidates.
showed
that
PPARγ
agonist
rosiglitazone
significantly
suppressed
reduced
without
cytotoxic
effects.
combination
rapamycin
prolonged
graft
survival.
Conclusions
defined
novel
effectively
predicts
agonists,
which
improve
when
combined
rapamycin.
Cardiology in Review,
Год журнала:
2025,
Номер
unknown
Опубликована: Март 21, 2025
Metabolic-associated
steatotic
liver
disease
(MASLD),
formerly
known
as
nonalcoholic
fatty
disease,
is
prevalent
worldwide
and
highly
associated
with
cardiovascular
(CVD).
Lean
MASLD
defined
by
hepatic
steatosis
cardiometabolic
risk
factors
in
individuals
a
body
mass
index
below
25
Western
populations
or
23
Asian
populations.
Paradoxically,
some
studies
indicate
that
lean
an
elevated
of
(CV)
CV
mortality
compared
nonlean
MASLD.
patients
exhibit
distinctive
metabolic,
genetic,
microbiome
profiles
contributing
to
increased
visceral
adiposity,
sarcopenia,
fibrosis,
systemic
inflammation,
endothelial
dysfunction.
This
review
examines
the
epidemiology,
pathophysiology,
outcomes
MASLD,
addressing
discrepancies
literature.
Furthermore,
it
highlights
current
clinical
guidelines,
emphasizes
lifestyle
modifications,
discusses
emerging
pharmacotherapies
potential
treatment
options.
Frontiers in Endocrinology,
Год журнала:
2025,
Номер
15
Опубликована: Янв. 21, 2025
Nucleotide-binding
oligomerization
domain
1
(NOD1)
is
an
intracellular
pattern
recognition
receptor
that
detects
injury
signals
and
initiates
inflammatory
responses
host
defense.
Furthermore,
NOD1
serves
as
a
metabolic
mediator
by
influencing
the
metabolism
of
various
tissues,
including
adipose
tissue,
liver,
cardiovascular
pancreatic
β
cells,
adrenal
glands,
bones
through
diverse
mechanisms.
It
has
been
discovered
activated
associated
with
pathological
mechanisms
certain
diseases.
This
review
presents
comprehensive
summary
impact
on
tissue-specific
metabolism.
